SCHEMBL1123219

SCHEMBL1123219

CCOC(=O)CCN(Cc1cccc(OCc2ccccc2)c1)C(=O)c1ccc(OCCOc2nc3ccccc3nc2C)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYSLTR2 Q9NS75 2/20 0.45
CYSLTR1 Q9Y271 2/20 0.45
MEN1 O00255 1/20 0.45
HSP90AA1 P07900 1/20 0.45
KMT2A Q03164 1/20 0.45
PPARG P37231 2/20 0.44
PPARA Q07869 2/20 0.44
PPARD Q03181 1/20 0.44
SLC2A1 P11166 6/20 0.44
SLC2A4 P14672 1/20 0.43
LTA4H P09960 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MMP13 P45452 1/20 0.41
PTGES O14684 2/20 0.41
ALOX5 P09917 1/20 0.40
LTC4S Q16873 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5720728 0.95 CYSLTR2 (0.45) CYSLTR2CYSLTR1MEN1HSP90AA1KMT2A
SCHEMBL1122873 0.92 SLC2A1 (0.45) CYSLTR2CYSLTR1MEN1HSP90AA1KMT2A
SCHEMBL1122770 0.92 SLC2A1 (0.46) CYSLTR2CYSLTR1MEN1HSP90AA1KMT2A
SCHEMBL1122604 0.87 SLC2A1 (0.52) MEN1KMT2ASLC2A1SLC2A4LTA4H
SCHEMBL1123226 0.87 L3MBTL1 (0.43) CYSLTR2CYSLTR1MEN1HSP90AA1KMT2A
SCHEMBL1123108 0.87 L3MBTL1 (0.45) CYSLTR2CYSLTR1KMT2APPARGPPARA
SCHEMBL1123430 0.87 PPARA (0.49) PPARGPPARASLC2A1SLC2A4L3MBTL1
SCHEMBL1123556 0.86 SLC2A1 (0.53) MEN1KMT2ASLC2A1SLC2A4LTA4H
SCHEMBL1122802 0.85 L3MBTL1 (0.47) CYSLTR2CYSLTR1MEN1HSP90AA1KMT2A
SCHEMBL1123188 0.84 SLC2A1 (0.52) MEN1KMT2ASLC2A1SLC2A4LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1644321-B1 NEW BENZAMIDES AS PPATY MODULATORS S A L V A T LAB SA (ES) 2011-02-09 EP disclosed
US-20060160894-A1 Benzamides as ppar modulators LABORATORIOS S.A.L.V.A.T.,S.A. (ES) 2006-07-20 US disclosed
EP-1644321-A2 NEW BENZAMIDES AS PPATY MODULATORS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2006-04-12 EP disclosed
WO-2004110983-A2 NEW BENZAMIDES AS PPARϒ MODULATORS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160894-A1 Benzamides as ppar modulators PPARD, PPARA, PPARG CYSLTR2 233/4885CYSLTR1 311/4885MEN1 4877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.